50 results
F-1
EX-10.7
SPRC
SciSparc Ltd
27 Feb 24
Registration statement (foreign)
4:15pm
of the option, Black-Scholes model or any other method). Inter alia, and without limitation of the following determination being made in other
F-1
SPRC
SciSparc Ltd
27 Feb 24
Registration statement (foreign)
4:15pm
the ability of selling our products. Volume of traffic and activity on eCommerce marketplaces spikes on certain days, such as during a Black Friday promotion … of this prospectus the FDA has approved only two pharmacological treatments for adult TS- haloperidol and pimozide – these treatments have a “black box
6-K
EX-10.1
SPRC
SciSparc Ltd
25 Jan 24
SciSparc Ltd. Announces $20 Million Standby Equity Purchase Agreement
9:05am
purchased pursuant to this Agreement, by (ii) the aggregate number of Shares issued pursuant to this Agreement.
“Black Out Period” shall have the meaning … Investor that a Material Outside Event has occurred, or (ii) the Company notifies the Investor of a Black Out Period, the parties agree
6-K
EX-99.1
SPRC
SciSparc Ltd
16 Oct 23
Interim Consolidated Financial Statements
5:00pm
2022 Warrants’ fair value was calculated using the Black–Scholes option pricing model, which takes into account the parameters as disclosed below
6-K
EX-99.2
ccgsgm
11 Jul 23
Report of Foreign Private Issuer
4:16pm
6-K
EX-99.1
0qknkth
29 Dec 22
Interim Consolidated Financial Statements
4:03pm
6-K
EX-99.2
9se iwz9lmzol4wvwz
11 Aug 22
Current Report
4:05pm
6-K
EX-99.2
nbggp54g83mkv4eijed
1 Jul 22
Current report (foreign)
4:00pm
6-K
EX-99.6
2qgt8glykmdfy b0h0y
27 May 22
SciSparc Announces Pricing of $10 Million Private Placement Priced At-the-Market
4:10pm
6-K
EX-99.5
jjc43
27 May 22
SciSparc Announces Pricing of $10 Million Private Placement Priced At-the-Market
4:10pm
6-K
EX-99.2
ad31n7
6 Jan 22
Report of Foreign Private Issuer
4:02pm
6-K
EX-99.1
135t rtjt
6 Jan 22
Report of Foreign Private Issuer
4:02pm
6-K
EX-99.1
dt0yp
6 Jan 22
SciSparc Announces Recruitment of First Patient for its Phase IIa Clinical Trial in Alzheimer’s Disease
9:09am
6-K/A
EX-99.1
xc9dafsvva0gissb78d
26 Aug 21
Current report (foreign) (amended)
4:42pm
6-K
EX-99.1
p5u494bm
16 Aug 21
Interim Consolidated Financial Statements
12:00am
6-K
EX-99.2
s00bn0xbc
25 Jun 21
Special General Meeting of Shareholders
4:01pm